Alastair Greystoke

Alastair Greystoke

Auto-generated profile, based on publicly available information

Alastair Greystoke

Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JHJian-Mei Hou
Jian-Mei Hou
MKMatthew G. Krebs
Matthew G. Krebs
LLLee Lancashire
Lee Lancashire
RSRobert Szczepaniak Sloane
Robert Szczepaniak Sloane
ABAlison Backen
Alison Backen
CDCaroline Dive
Caroline Dive
Purpose: Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and “virtual” biopsies. We report the clinical significance and molecular characteristics of CTCs and CTC clusters, termed circulating tumor microemboli (CTM), detected in patients with small-cell lung cancer (SCLC) undergoing standard treatment. Patients and Methods: Serial blood samples from 97 patients receiving chemotherapy were analyzed using EpCam-based immunomagnetic detection and a filtration-based technique. Proliferation status (Ki67) and apoptotic morphology were examined. Associations of CTC and CTM number with clinical factors and prognosis were determined. Results: CTCs were present in 85% of patients (77 of 97 patients) and were abundant (mean ± standard deviation = 1,589 ± 5,565). CTM and apoptotic CTCs were correlated with total CTC number and were detected in 32% and 57% of patients, respectively. Pretreatment CTCs, change in CTC number after one cycle of chemotherapy, CTM, and apoptotic CTCs were independent prognostic factors. Overall survival was 5.4 months for patients with ≥ 50 CTCs/7.5 mL of blood and 11.5 months (P < .0001) for patients with less than 50 CTCs/7.5 mL of blood before chemotherapy (hazard ratio = 2.45; 95% CI, 1.39 to 4.30; P = .002). Subpopulations of apoptotic and of proliferating solitary CTCs were detected, whereas neither were observed within cell clusters (CTM), implicating both protection from anoikis and relative resistance to cytotoxic drugs for cells within CTM. Conclusion: Both baseline CTC number and change in CTC number after one cycle of chemotherapy are independent prognostic factors for SCLC. Molecular comparison of CTCs to cells in CTM may provide novel insights into SCLC biology.

20 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMatthew G. Krebs
Matthew G. Krebs
RSRobert Szczepaniak Sloane
Robert Szczepaniak Sloane
LPLynsey Priest
Lynsey Priest
LLLee Lancashire
Lee Lancashire
JHJian-Mei Hou
Jian-Mei Hou
FBFiona Blackhall
Fiona Blackhall
Purpose: Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This study investigated whether circulating tumor cells (CTCs) are detectable in patients with NSCLC and what their ability might be to provide prognostic information and/or early indication of patient response to conventional therapy. Patients and Methods: In this single-center prospective study, blood samples for CTC analysis were obtained from 101 patients with previously untreated, stage III or IV NSCLC both before and after administration of one cycle of standard chemotherapy. CTCs were measured using a semiautomated, epithelial cell adhesion molecule–based immunomagnetic technique. Results: The number of CTCs in 7.5 mL of blood was higher in patients with stage IV NSCLC (n = 60; range, 0 to 146) compared with patients with stage IIIB (n = 27; range, 0 to 3) or IIIA disease (n = 14; no CTCs detected). In univariate analysis, progression-free survival was 6.8 v 2.4 months with P < .001, and overall survival (OS) was 8.1 v 4.3 months with P < .001 for patients with fewer than five CTCs compared with five or more CTCs before chemotherapy, respectively. In multivariate analysis, CTC number was the strongest predictor of OS (hazard ratio [HR], 7.92; 95% CI, 2.85 to 22.01; P < .001), and the point estimate of the HR was increased with incorporation of a second CTC sample that was taken after one cycle of chemotherapy (HR, 15.65; 95% CI, 3.63 to 67.53; P < .001). Conclusion: CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease. Further validation is warranted before routine clinical application.

1 June 2014 in Nature Medicine
Verified
Journal Article
Closed access
CHCassandra L Hodgkinson
Cassandra L Hodgkinson
CMChristopher J Morrow
Christopher J Morrow
YLYaoyong Li
Yaoyong Li
RMRobert L Metcalf
Robert L Metcalf
DRDominic Rothwell
Dominic Rothwell
CDCaroline Dive
Caroline Dive

18 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SHSarah Halford
Sarah Halford
Northern Institute for Cancer ResearchNorthern Institute for Cancer Research
Northern Institute for Cancer Research
SWStephen R. Wedge
Stephen R. Wedge
GPGeoffrey S. Payne
Geoffrey S. Payne
CBChris M. Bacon
Chris M. Bacon
RPRuth Plummer
Ruth Plummer
Purpose: Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-class MCT1 inhibitor, in advanced cancer. Patients and Methods: This multicentre, phase I, dose-escalation and dose-expansion trial enrolled patients with advanced solid tumors or lymphoma and no standard therapy options. Exclusion criteria included history of retinal and/or cardiac disease, due to MCT1 expression in the eye and heart. Patients received daily oral AZD3965 according to a 3+3 then rolling six design. Primary objectives were to assess safety and determine the MTD and/or recommended phase II dose (RP2D). Secondary objectives for dose escalation included measurement of pharmacokinetic and pharmacodynamic activity. Exploratory biomarkers included tumor expression of MCT1 and MCT4, functional imaging of biological impact, and metabolomics. Results: During dose escalation, 40 patients received AZD3965 at 5–30 mg once daily or 10 or 15 mg twice daily. Treatment-emergent adverse events were primarily grade 1 and/or 2, most commonly electroretinogram changes (retinopathy), fatigue, anorexia, and constipation. Seven patients receiving ≥20 mg daily experienced dose-limiting toxicities (DLT): grade 3 cardiac troponin rise (n = 1), asymptomatic ocular DLTs (n = 5), and grade 3 acidosis (n = 1). Plasma pharmacokinetics demonstrated attainment of target concentrations; pharmacodynamic measurements indicated on-target activity. Conclusions: AZD3965 is tolerated at doses that produce target engagement. DLTs were on-target and primarily dose-dependent, asymptomatic, reversible ocular changes. An RP2D of 10 mg twice daily was established for use in dose expansion in cancers that generally express high MCT1/low MCT4).

1 August 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
JHJian-Mei Hou
Jian-Mei Hou
AGAlastair Greystoke
Alastair Greystoke
LLLee Lancashire
Lee Lancashire
JCJeff Cummings
Jeff Cummings
TWTim Ward
Tim Ward
FBFiona Blackhall
Fiona Blackhall

28 January 2010 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
RBRuth E. Board
Ruth E. Board
AWAndrew M Wardley
Andrew M Wardley
JDJ. Michael Dixon
J. Michael Dixon
AAAnne C. Armstrong
Anne C. Armstrong
SHsacha howell
sacha howell
CDCaroline Dive
Caroline Dive